JP2016506388A5 - - Google Patents

Download PDF

Info

Publication number
JP2016506388A5
JP2016506388A5 JP2015545868A JP2015545868A JP2016506388A5 JP 2016506388 A5 JP2016506388 A5 JP 2016506388A5 JP 2015545868 A JP2015545868 A JP 2015545868A JP 2015545868 A JP2015545868 A JP 2015545868A JP 2016506388 A5 JP2016506388 A5 JP 2016506388A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
nos
sequence consisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015545868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506388A (ja
JP6499971B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/073540 external-priority patent/WO2014089416A1/en
Publication of JP2016506388A publication Critical patent/JP2016506388A/ja
Publication of JP2016506388A5 publication Critical patent/JP2016506388A5/ja
Application granted granted Critical
Publication of JP6499971B2 publication Critical patent/JP6499971B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015545868A 2012-12-07 2013-12-06 抗ｃｄ３８抗体及びレナリドマイドを含む組成物 Active JP6499971B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261734524P 2012-12-07 2012-12-07
US61/734,524 2012-12-07
US201361769247P 2013-02-26 2013-02-26
US61/769,247 2013-02-26
US201361808372P 2013-04-04 2013-04-04
US61/808,372 2013-04-04
PCT/US2013/073540 WO2014089416A1 (en) 2012-12-07 2013-12-06 Compositions comprising anti-cd38 antibodies and lenalidomide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019003132A Division JP2019070020A (ja) 2012-12-07 2019-01-11 抗ｃｄ３８抗体及びレナリドマイドを含む組成物

Publications (3)

Publication Number Publication Date
JP2016506388A JP2016506388A (ja) 2016-03-03
JP2016506388A5 true JP2016506388A5 (en:Method) 2017-01-19
JP6499971B2 JP6499971B2 (ja) 2019-04-10

Family

ID=50884019

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015545868A Active JP6499971B2 (ja) 2012-12-07 2013-12-06 抗ｃｄ３８抗体及びレナリドマイドを含む組成物
JP2019003132A Pending JP2019070020A (ja) 2012-12-07 2019-01-11 抗ｃｄ３８抗体及びレナリドマイドを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019003132A Pending JP2019070020A (ja) 2012-12-07 2019-01-11 抗ｃｄ３８抗体及びレナリドマイドを含む組成物

Country Status (31)

Country Link
EP (2) EP2928495B1 (en:Method)
JP (2) JP6499971B2 (en:Method)
KR (2) KR102193045B1 (en:Method)
CN (1) CN105263520B (en:Method)
AR (1) AR093844A1 (en:Method)
AU (2) AU2013355064B2 (en:Method)
BR (1) BR112015012987A2 (en:Method)
CA (1) CA2893946A1 (en:Method)
CL (2) CL2015001558A1 (en:Method)
CY (2) CY1122478T1 (en:Method)
DK (1) DK2928495T3 (en:Method)
ES (1) ES2731548T3 (en:Method)
HR (1) HRP20191034T1 (en:Method)
HU (3) HUE044142T2 (en:Method)
IL (2) IL239234B (en:Method)
LT (2) LT2928495T (en:Method)
LU (1) LUC00187I2 (en:Method)
MX (2) MX366296B (en:Method)
MY (1) MY191601A (en:Method)
NL (1) NL301079I2 (en:Method)
NZ (1) NZ709215A (en:Method)
PH (1) PH12015501263A1 (en:Method)
PL (1) PL2928495T3 (en:Method)
PT (1) PT2928495T (en:Method)
RS (1) RS58829B1 (en:Method)
RU (1) RU2698911C2 (en:Method)
SG (3) SG10201913783PA (en:Method)
SI (1) SI2928495T1 (en:Method)
TW (2) TWI670062B (en:Method)
UA (1) UA118255C2 (en:Method)
WO (1) WO2014089416A1 (en:Method)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2015195555A1 (en) * 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
WO2016022589A2 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
TWI721959B (zh) 2014-12-04 2021-03-21 美商健生生物科技公司 治療急性骨髓性白血病之抗ｃｄ３８抗體
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
NZ777133A (en) 2015-06-22 2025-05-02 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
SMT202100192T1 (it) 2015-11-03 2021-05-07 Janssen Biotech Inc Formulazioni sottocutanee di anticorpi anti-cd38 e loro usi.
CN109689690B (zh) 2016-07-15 2023-10-03 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
WO2019199132A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 다양한 용량의 레날리도마이드의 경구용 정제 조성물
KR102286498B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드의 경구용 코팅 정제 조성물
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
JP7585043B2 (ja) * 2018-04-13 2024-11-18 サムヤン ホールディングス コーポレイション レナリドミドを含む医薬組成物
MY205856A (en) 2018-05-16 2024-11-15 Stichting Vumc Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
IL281845B2 (en) * 2018-10-01 2025-06-01 Celgene Corp Combination therapy comprising 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and daratumumab for the treatment multiple myeloma
US20220144965A1 (en) * 2019-03-15 2022-05-12 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US20220241413A1 (en) * 2019-06-10 2022-08-04 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
TWI865644B (zh) * 2019-10-31 2024-12-11 德商莫菲西斯公司 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
BR112022010905A2 (pt) 2019-12-05 2022-09-06 Sanofi Aventis Us Llc Formulações de anticorpos anti-cd38 para administração subcutânea
US20250277051A1 (en) * 2021-08-02 2025-09-04 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2006068185A1 (ja) * 2004-12-21 2006-06-29 Nippon Kayaku Kabushki Kaisha エポキシ樹脂、エポキシ樹脂組成物及びその硬化物
NZ561883A (en) * 2005-03-23 2010-11-26 Genmab As Antibodies against CD38 for treatment of multiple myeloma
HUE044136T2 (hu) * 2006-09-26 2019-09-30 Genmab As Anti-CD38 plusz kortikoszteroidok plusz nem-kortikoszteroid kemoterápiás szer daganatok kezelésére
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
PT2621531T (pt) 2010-09-27 2017-03-13 Morphosys Ag Anticorpo anti-cd38 e lenalidomida ou bortezomibe para o tratamento de mieloma múltiplo e linfoma não-hodgkins
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38

Similar Documents

Publication Publication Date Title
JP2016506388A5 (en:Method)
JP2016514148A5 (en:Method)
RU2015127089A (ru) Композиции, содержащие антитела к cd38 и леналидомид
JP2016536314A5 (en:Method)
JP2014076062A5 (en:Method)
JP2017048208A5 (en:Method)
RU2015143462A (ru) Композиции, включающие антитела к cd38 и карфилзомиб
JP2013537418A5 (en:Method)
FI3932951T3 (fi) Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria
JP2018534933A5 (en:Method)
JP2014533279A5 (en:Method)
RU2018105846A (ru) Комбинация антагониста pd-1 с ингибитором egfr
HRP20201656T1 (hr) Neutralizacija inhibitornih putova u limfocitima
JP2010500370A5 (en:Method)
JP2019531764A5 (en:Method)
RU2015110981A (ru) Комбинации и их применение
JP2015532292A5 (en:Method)
JP2020503891A5 (en:Method)
JP2017507954A5 (en:Method)
JP2010500371A5 (en:Method)
JP2017515815A5 (en:Method)
JP2012523417A5 (en:Method)
JP2017525730A5 (en:Method)
JP2017503820A5 (en:Method)
JP2012136541A5 (en:Method)